Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.83 |
| ▸ | BTK | Q06187 | 7/20 | 0.83 |
| ▸ | ITK | Q08881 | 6/20 | 0.83 |
| ▸ | TEC | P42680 | 3/20 | 0.83 |
| ▸ | BMX | P51813 | 3/20 | 0.83 |
| ▸ | TXK | P42681 | 2/20 | 0.83 |
| ▸ | LYN | P07948 | 2/20 | 0.83 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.83 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.83 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.83 |
| ▸ | LATS1 | O95835 | 1/20 | 0.83 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.83 |
| ▸ | ABL1 | P00519 | 1/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.83 |
| ▸ | LCK | P06239 | 1/20 | 0.83 |
| ▸ | FYN | P06241 | 1/20 | 0.83 |
| ▸ | PGR | P06401 | 1/20 | 0.83 |
| ▸ | CSF1R | P07333 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19097665 | 1.00 | EGFR (0.83) | EGFRBTKITKTECBMX | |
| SCHEMBL15613679 | 0.93 | BTK (0.84) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL201642 | 0.91 | BTK (1.00) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL2244870 | 0.91 | BTK (1.00) | EGFRBTKITKTECBMX | |
| SCHEMBL15697616 | 0.91 | EGFR (0.85) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL2244865 | 0.91 | BTK (1.00) | EGFRBTKITKTECBMX | |
| SCHEMBL17779420 | 0.91 | EGFR (0.85) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL201859 | 0.91 | BTK (1.00) | EGFRBTKITKTECBMX | |
| Ibrutinib SCHEMBL201641 | 0.91 | BTK (1.00) | EGFRBTKITKTECBMX | |
| SCHEMBL12713491 | 0.90 | EGFR (1.00) | EGFRBTKITKTECBMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3398950-B1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| EP-3398950-B1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | PRECEDO PHARMACEUTICALS CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-106928231-B | Novel EGFR wild type and mutant kinase inhibitors | 合肥中科普瑞昇生物医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | PRECEDO PHARMACEUTICALS CO., LTD. (CN) | 2020-09-22 | — | — | US | disclosed |
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-01-10 | — | — | US | disclosed |
| EP-3398950-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE EGFR AND MUTATED EGFR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010159-A1 | NOVEL KINASE INHIBITOR AGAINST WILD-TYPE AND MUTANT EGFR | EGFR, ERBB2, ERBB3 | EGFR 1/4885BTK 680/4885ITK 1083/4885 |
| US-10781214-B2 | Kinase inhibitor against wild-type and mutant EGFR | EGFR, ERBB2, ERBB3 | EGFR 1/4885BTK 632/4885ITK 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.